Next Article in Journal / Special Issue
Natural and Induced Humoral Responses to MUC1
Previous Article in Journal
Dual Targeting of the Insulin-Like Growth Factor and Collateral Pathways in Cancer: Combating Drug Resistance
Previous Article in Special Issue
Immune Suppression in Tumors as a Surmountable Obstacle to Clinical Efficacy of Cancer Vaccines
Cancers 2011, 3(3), 3055-3072; doi:10.3390/cancers3033055

Immunotherapy for Urothelial Carcinoma: Current Status and Perspectives

*  and
Department of Urology, Sapporo Medical University School of Medicine, South 1 West 16, Chuo-ku, Sapporo 060-8543, Japan
* Author to whom correspondence should be addressed.
Received: 7 June 2011 / Revised: 22 July 2011 / Accepted: 26 July 2011 / Published: 29 July 2011
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
View Full-Text   |   Download PDF [527 KB, uploaded 29 July 2011]   |   Browse Figure


Intravesical instillation of bacillus Calmette Guérin (BCG) for the treatment of urothelial carcinoma (UC) of the bladder is based on the BCG-induced immune response, which eradicates and prevents bladder cancer. The results of recent studies have suggested that not only major histocompatibility complex (MHC)-nonrestricted immune cells such as natural killer cells, macrophages, neutrophils, etc., but also MHC-restricted CD8+ T cells play an important role and are one of the main effectors in this therapy. Better understanding of the mechanism of BCG immunotherapy supports the idea that active immunotherapy through its augmented T cell response can have great potential for the treatment of advanced UC. In this review, progress in immunotherapy for UC is discussed based on data from basic, translational and clinical studies. We also review the escape mechanism of cancer cells from the immune system, and down-regulation of MHC class I molecules.
Keywords: immunotherapy; urothelial cancer; cancer vaccine immunotherapy; urothelial cancer; cancer vaccine
This is an open access article distributed under the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Kitamura, H.; Tsukamoto, T. Immunotherapy for Urothelial Carcinoma: Current Status and Perspectives. Cancers 2011, 3, 3055-3072.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert